Melatonin is often sold as a gentle sleeping pill. The biology is narrower than that. It is a darkness signal that helps time the circadian clock, and the evidence is stronger for some timing problems than for chronic insomnia. Used casually, especially at high doses or for months, it can create more uncertainty than benefit.
Melatonin is a clock signal first
The body makes melatonin in response to darkness. The National Center for Complementary and Integrative Health describes it as a hormone involved in the timing of circadian rhythms and sleep, not as a sedative that simply switches the brain off (NCCIH’s May 2024 melatonin overview). That distinction matters because many sleep problems are not timing problems.
Sleep pressure, the drive that builds the longer we stay awake, is separate from circadian timing. A person can have plenty of melatonin in the evening and still be alert because stress, pain, caffeine, alcohol, sleep apnoea, restless legs, or an irregular schedule is keeping the arousal system active. In that situation, more melatonin does not address the main mechanism.
The science is clearer for nudging a delayed clock than for forcing sleep on demand. Someone whose body naturally wants to fall asleep at 2 a.m. may be dealing with a circadian phase that is late relative to work, school, or family life. Someone who wakes at 3 a.m. and cannot return to sleep may have a different problem entirely.
Where the evidence is strongest
Delayed sleep-wake phase disorder is the cleanest example. People with this pattern struggle to fall asleep at conventional times and prefer to wake much later. NCCIH summarises evidence that timed melatonin can help some people with delayed sleep-wake phase disorder, although the certainty and harms question remain cautious (NCCIH on delayed sleep-wake phase disorder).
One important trial in PLOS Medicine tested melatonin alongside behavioural sleep-wake scheduling in adults with delayed sleep-wake phase disorder. The intervention was not “take a tablet whenever you feel wired”; participants took melatonin one hour before their desired bedtime and followed a set sleep schedule (the 2018 randomised clinical trial in PLOS Medicine). That is a circadian treatment package, not a general sleep-aid habit.
Jet lag is another timing problem, although the evidence base is older and mixed in quality. The practical point is still circadian: light exposure, destination bedtime, meals, and wake time all pull the clock. Melatonin may help some adults when the dose is timed to the new night, but it is less likely to help if used as a blanket remedy for any tiredness after travel.
Why insomnia is a different question
Chronic insomnia means trouble falling asleep, staying asleep, or waking too early for at least a month, with daytime impairment. It is not one disease. It can involve conditioned arousal, anxiety, depression, pain, medicines, alcohol, sleep apnoea, circadian delay, or a mixture of factors.
This is why guideline language is cautious. The American Academy of Sleep Medicine’s pharmacological guideline suggests that clinicians should not use melatonin for sleep-onset or sleep-maintenance insomnia in adults (the 2017 AASM clinical practice guideline). NCCIH also notes that AASM and American College of Physicians guidance does not find strong enough evidence or safety data to recommend melatonin for chronic insomnia, whilst the ACP recommends cognitive behavioural therapy for insomnia as initial treatment (NCCIH’s summary of insomnia guidance).
That does not mean no one ever sleeps faster after taking it. It means the clinical case is weaker than the supplement shelf suggests. A short-term nudge for a shifted clock is one thing. Nightly use for persistent insomnia, without checking for the cause, is another.
Timing may matter more than the label suggests
Most people who use melatonin take it close to lights-out. The circadian literature is more awkward. A 2024 systematic review and dose-response meta-analysis in the Journal of Pineal Research found that dose and timing both influenced sleep outcomes, and the authors suggested that taking melatonin earlier than the common 30-minute pre-bed routine may produce stronger sleep-promoting effects (the 2024 dose-response meta-analysis).
That finding should not be turned into a universal protocol. The review pooled trials with different populations and designs, and the right timing depends on what problem is being treated. Taken at the wrong biological time, melatonin could theoretically shift the clock in an unhelpful direction. This is why circadian clinicians often think in terms of phase, light exposure, wake time, and desired bedtime rather than “stronger” or “weaker” supplements.
Dose is similarly easy to misunderstand. More is not automatically better. Higher doses may linger, especially in older adults, and can leave some people groggy the next day. The useful dose for a clock shift may be lower than many over-the-counter products imply.
The product on the shelf is another uncertainty
Melatonin’s evidence is one question. The supplement product is another. In the United States, melatonin is regulated as a dietary supplement rather than as a prescription medicine. NCCIH notes that some products may not contain what the label states, and that regulation is less strict than for prescription or over-the-counter medicines (NCCIH on supplement regulation and label accuracy).
A 2017 study in the Journal of Clinical Sleep Medicine tested commercial melatonin products and found large variability between labelled and measured melatonin content; some products also contained serotonin (the 2017 supplement-content study). That does not prove every product is inaccurate, but it does make casual dose comparisons unreliable.
This is the part of the melatonin story that often gets missed. A trial result using a controlled preparation does not map neatly onto a gummy or tablet bought online. The compound may be familiar; the manufacturing chain may still be uneven.
Who should be especially cautious
Melatonin is usually discussed as mild, and short-term use appears safe for many adults. The safety question changes when use becomes long-term, high-dose, or medically complicated. NCCIH states that long-term safety data are lacking, and flags supervision for people with epilepsy or those taking blood-thinning medicines (NCCIH’s melatonin safety guidance).
Pregnancy and breastfeeding are also areas where the evidence is thin. Older adults may metabolise melatonin more slowly, raising the chance of daytime drowsiness. People with dementia are a separate caution group in sleep-medicine guidance. Anyone using sedatives, alcohol, psychiatric medicines, anticoagulants, anti-seizure medicines, or medicines that already affect alertness should treat melatonin as a substance to discuss, not a harmless add-on.
Children need particular care. This article is focused on adults, but child and adolescent use raises different dose, development, and accidental-ingestion issues. Parents should not extrapolate from adult sleep advice.
What this means in practice
- Separate timing problems from insomnia. A late body clock, jet lag, and night waking are not the same sleep problem.
- If poor sleep lasts for weeks, or causes daytime impairment, discuss it with a clinician rather than escalating supplement dose.
- Look for causes melatonin cannot fix: caffeine timing, alcohol, stress, pain, medicines, snoring, possible sleep apnoea, and irregular wake times.
- If melatonin is being considered, treat timing as the key variable and avoid assuming that a larger dose is more effective.
- Check medication interactions and medical context, especially with epilepsy, blood thinners, pregnancy, breastfeeding, dementia, or older age.
- Keep supplements out of children’s reach, particularly gummies and flavoured products.
What we don’t know
We do not yet have clean answers on long-term nightly melatonin use in healthy adults. Many trials are short, use different doses, and measure sleep outcomes in different ways. The evidence is also stronger for some circadian problems than for chronic insomnia, which is often sustained by arousal, behaviour, and medical context rather than by a simple lack of melatonin.
There is also a translation problem. Clinical trials and guidelines evaluate defined preparations, populations, and outcomes. Consumers buy variable products, often without a diagnosis, and use them for problems that may need another approach. That gap is where overconfident advice tends to grow.
Melatonin is not nonsense, and it is not a nightly longevity habit. It is a timing signal with a narrow evidence base, real uncertainties, and enough medical context to deserve more care than the supplement aisle gives it.
Photo: Lisa Anna on Unsplash.